Otherwise, the American Diabetes Association and the European Association for the Study of Diabetes [79] recommend SGLT2-i or GLP-1RA as hypoglycemic agents for patients at high risk of cardiovascular disease, and studies [11] have shown that SGLT2-i or GLP-1RA may reduce the risk of stroke in patients with T2DM. Here, SLC5A2 is linked to stroke disorder.